Current File : //var/www/html/shaban/duassis/api/public/storage/q8q7nfc/cache/76d7d43b0d8afec618f24185f89db492
a:5:{s:8:"template";s:7286:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Lato%3A300%2C400%7CMerriweather%3A400%2C700&ver=5.4" id="siteorigin-google-web-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,header,nav{display:block}a{background-color:transparent}svg:not(:root){overflow:hidden}button{color:inherit;font:inherit;margin:0}button{overflow:visible}button{text-transform:none}button{-webkit-appearance:button;cursor:pointer}button::-moz-focus-inner{border:0;padding:0}html{font-size:93.75%}body,button{color:#626262;font-family:Merriweather,serif;font-size:15px;font-size:1em;-webkit-font-smoothing:subpixel-antialiased;-moz-osx-font-smoothing:auto;font-weight:400;line-height:1.8666}.site-content{-ms-word-wrap:break-word;word-wrap:break-word}html{box-sizing:border-box}*,:after,:before{box-sizing:inherit}body{background:#fff}ul{margin:0 0 2.25em 2.4em;padding:0}ul li{padding-bottom:.2em}ul{list-style:disc}button{background:#fff;border:2px solid;border-color:#ebebeb;border-radius:0;color:#2d2d2d;font-family:Lato,sans-serif;font-size:13.8656px;font-size:.8666rem;line-height:1;letter-spacing:1.5px;outline-style:none;padding:1em 1.923em;transition:.3s;text-decoration:none;text-transform:uppercase}button:hover{background:#fff;border-color:#24c48a;color:#24c48a}button:active,button:focus{border-color:#24c48a;color:#24c48a}a{color:#24c48a;text-decoration:none}a:focus,a:hover{color:#00a76a}a:active,a:hover{outline:0}.main-navigation{align-items:center;display:flex;line-height:1}.main-navigation:after{clear:both;content:"";display:table}.main-navigation>div{display:inline-block}.main-navigation>div ul{list-style:none;margin:0;padding-left:0}.main-navigation>div li{float:left;padding:0 45px 0 0;position:relative}.main-navigation>div li:last-child{padding-right:0}.main-navigation>div li a{text-transform:uppercase;color:#626262;font-family:Lato,sans-serif;font-size:.8rem;letter-spacing:1px;padding:15px;margin:-15px}.main-navigation>div li:hover>a{color:#2d2d2d}.main-navigation>div a{display:block;text-decoration:none}.main-navigation>div ul{display:none}.menu-toggle{display:block;border:0;background:0 0;line-height:60px;outline:0;padding:0}.menu-toggle .svg-icon-menu{vertical-align:middle;width:22px}.menu-toggle .svg-icon-menu path{fill:#626262}#mobile-navigation{left:0;position:absolute;text-align:left;top:61px;width:100%;z-index:10}.site-content:after:after,.site-content:before:after,.site-footer:after:after,.site-footer:before:after,.site-header:after:after,.site-header:before:after{clear:both;content:"";display:table}.site-content:after,.site-footer:after,.site-header:after{clear:both}.container{margin:0 auto;max-width:1190px;padding:0 25px;position:relative;width:100%}@media (max-width:480px){.container{padding:0 15px}}.site-content:after{clear:both;content:"";display:table}#masthead{border-bottom:1px solid #ebebeb;margin-bottom:80px}.header-design-2 #masthead{border-bottom:none}#masthead .sticky-bar{background:#fff;position:relative;z-index:101}#masthead .sticky-bar:after{clear:both;content:"";display:table}.sticky-menu:not(.sticky-bar-out) #masthead .sticky-bar{position:relative;top:auto}#masthead .top-bar{background:#fff;border-bottom:1px solid #ebebeb;position:relative;z-index:9999}#masthead .top-bar:after{clear:both;content:"";display:table}.header-design-2 #masthead .top-bar{border-top:1px solid #ebebeb}#masthead .top-bar>.container{align-items:center;display:flex;height:60px;justify-content:space-between}#masthead .site-branding{padding:60px 0;text-align:center}#masthead .site-branding a{display:inline-block}#colophon{clear:both;margin-top:80px;width:100%}#colophon .site-info{border-top:1px solid #ebebeb;color:#626262;font-size:13.8656px;font-size:.8666rem;padding:45px 0;text-align:center}@media (max-width:480px){#colophon .site-info{word-break:break-all}}@font-face{font-family:Lato;font-style:normal;font-weight:300;src:local('Lato Light'),local('Lato-Light'),url(http://fonts.gstatic.com/s/lato/v16/S6u9w4BMUTPHh7USSwiPHA.ttf) format('truetype')}@font-face{font-family:Lato;font-style:normal;font-weight:400;src:local('Lato Regular'),local('Lato-Regular'),url(http://fonts.gstatic.com/s/lato/v16/S6uyw4BMUTPHjx4wWw.ttf) format('truetype')}@font-face{font-family:Merriweather;font-style:normal;font-weight:400;src:local('Merriweather Regular'),local('Merriweather-Regular'),url(http://fonts.gstatic.com/s/merriweather/v21/u-440qyriQwlOrhSvowK_l5-fCZJ.ttf) format('truetype')}@font-face{font-family:Merriweather;font-style:normal;font-weight:700;src:local('Merriweather Bold'),local('Merriweather-Bold'),url(http://fonts.gstatic.com/s/merriweather/v21/u-4n0qyriQwlOrhSvowK_l52xwNZWMf_.ttf) format('truetype')} </style>
</head>
<body class="cookies-not-set css3-animations hfeed header-design-2 no-js page-layout-default page-layout-hide-masthead page-layout-hide-footer-widgets sticky-menu sidebar wc-columns-3">
<div class="hfeed site" id="page">
<header class="site-header" id="masthead">
<div class="container">
<div class="site-branding">
<a href="#" rel="home">
{{ keyword }}</a> </div>
</div>
<div class="top-bar sticky-bar sticky-menu">
<div class="container">
<nav class="main-navigation" id="site-navigation" role="navigation">
<button aria-controls="primary-menu" aria-expanded="false" class="menu-toggle" id="mobile-menu-button"> <svg class="svg-icon-menu" height="32" version="1.1" viewbox="0 0 27 32" width="27" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<path d="M27.429 24v2.286q0 0.464-0.339 0.804t-0.804 0.339h-25.143q-0.464 0-0.804-0.339t-0.339-0.804v-2.286q0-0.464 0.339-0.804t0.804-0.339h25.143q0.464 0 0.804 0.339t0.339 0.804zM27.429 14.857v2.286q0 0.464-0.339 0.804t-0.804 0.339h-25.143q-0.464 0-0.804-0.339t-0.339-0.804v-2.286q0-0.464 0.339-0.804t0.804-0.339h25.143q0.464 0 0.804 0.339t0.339 0.804zM27.429 5.714v2.286q0 0.464-0.339 0.804t-0.804 0.339h-25.143q-0.464 0-0.804-0.339t-0.339-0.804v-2.286q0-0.464 0.339-0.804t0.804-0.339h25.143q0.464 0 0.804 0.339t0.339 0.804z"></path>
</svg>
</button>
<div class="menu-menu-1-container"><ul class="menu" id="primary-menu"><li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-20" id="menu-item-20"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-165" id="menu-item-165"><a href="#">Blog</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-24" id="menu-item-24"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-22" id="menu-item-22"><a href="#">Contacts</a></li>
</ul></div> </nav>
<div id="mobile-navigation"></div>
</div>
</div>
</header>
<div class="site-content" id="content">
<div class="container">
{{ text }}
<br>
{{ links }}
</div>
</div>
<footer class="site-footer " id="colophon">
<div class="container">
</div>
<div class="site-info">
<div class="container">
{{ keyword }} 2021</div>
</div>
</footer>
</div>
</body>
</html>";s:4:"text";s:12105:"Dengvaxia is the result of over 20 years of research and development and is the first vaccine approved for the prevention of dengue, a serious mosquito-borne disease that weighs heavily on public health systems throughout the world. When deciding whether to get the vaccine, it’s important to separate myths from facts. The Dengvaxia vaccine was a promising solution to the scourge of dengue, a mosquito-borne disease to which hundreds of thousands of Filipinos fall victim each year. In May 2019, Dengvaxia® was approved by the U.S. Food and Drug Administration (FDA) in the United States for use in children 9-16 years old living in an area where dengue is common (the US territories of American Samoa, Puerto Rico and the US Virgin Islands), with laboratory confirmed prior dengue virus infection. Dengvaxia, manufactured by Sanofi Pasteur, has been licensed, but it has variable efficacy against the four dengue serotypes and an overall efficacy of only 56%. MANILA, Philippines — It cannot be denied the Dengvaxia issue contributed to Filipinos’ hesitancy over COVID-19 vaccines. It’s a remarkable vaccine that greatly reduces the chance of suffering from a severe case of dengue. But in … He explains that when administered to seronegatives, Dengvaxia acts like a first infection, priming the body to develop severe dengue once the person is bitten by an actual mosquito. Many people are excited to have vaccines as the first step in managing the spread of coronavirus. (Actually, AstraZeneca reported conducting trials of its coronavirus vaccine on 20,000 volunteers around the world. A trial was conducted involving 30,000 people, including in the Philippines. But this vaccine has a dark — and deadly — history. Blame for deaths directly caused by the vaccine Dengvaxia was the unabashed objective of Persida’s performance, as salaciously coveted by her boss, Aguirre. In a world of wild talk and fake news, help us stand up for the facts. All four virus types occur worldwide, also in the Philippines. Early diagnosis and supportive treatment once a patient has the disease can only limit or alleviate polio’s symptoms, which may include fever, paralysis or weakness of both extremities, muscle pain, stiffness of the neck and back, and difficulty of breathing. Dengue Dengue fever is a disease transmitted by the bite of the Aedes mosquito carrying one of the 4 dengue viruses. Dengue tetravalent vaccine, live is used to prevent dengue disease in children 9 to 16 years of age with a previous laboratory-confirmed dengue infection and who are living in endemic (where the disease is common) areas. Dengvaxia successfully completes its two parallel Phase 3 clinical studies, which compare the safety and effectiveness of the new treatment. In the five years after the trial, the chance of suffering from severe dengue was reduced by 93 percent; the overall reduction was 65 percent. Instead, the ensuing Dengvaxia publicity has given vaccination a bad rap. In November 2017, the results of an additional analysis to retrospectively determine serostatus at the time of vaccination were released. This vaccine is to be given only by or under the direct supervision of your doctor. 1 The other two lead candidate vaccines, developed by CDC/Takeda (TAK-003) 2 and NIH/Merck (TV003/TV005), 3 are still in phase III efficacy trials. The analysis showed that the Dengvaxia is approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in … Trials showed that in patients 9 years and older, Dengvaxia can reduce instances of severe dengue by 90% and decrease the risk of hospitalization from dengue by 80%. Halstead suggests a new candidate dengue vaccine that NIH is testing in 17,000 people in Brazil could offer protection to young people at risk of ADE. 544. It was not an NIH-made dengue vaccine but Dengvaxia, produced by the French pharmaceutical company Sanofi Pasteur, that was given to over 830,000 public school students in the Philippines during the implementation of the controversial dengue immunization program of the Department of Health (DOH). Dengvaxia is approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas. About 390 million people are infected by dengue each year in some 120 countries, particularly in Southeast Asia, … The … Dengvaxia carries the risk of “severe” dengue for two out of 4,000 recipients. Get answers to many of your COVID-19 vaccine questions. A dengue vaccine, called Dengvaxia, recently became available in Mexico, Brazil, the Philippines and El Salvador. The COVID-19 Vaccine: Myths vs. Facts. Dengvaxia (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. What has been lost is the fact that no drug is perfect, no drug works 100 percent. A Filipino scientist on Thursday blamed the Dengvaxia controversy on “bad science.”. The recent brouhaha over a vaccine called Dengvaxia (touted to be the world’s first Dengue vaccine) is a classic example of the deleterious effects of malice in social media morphing into near hysteria. Posted at Feb 02 2018 08:41 PM. Unfortunately, there has been a lot of misinformation surrounding the vaccines and their development. Dengvaxia ® (also referred to as CYD-TDV), developed by Sanofi Pasteur, is a live recombinant tetravalent dengue vaccine, based on the yellow fever 17D vaccine strain, given as a 3-dose series with 6 months between each dose. On Dec. 21, 2018, Sanofi was ordered to surrender the original CPRs of dengue tetravalent (Dengvaxia MD) and dengue tetravalent vaccine (Dengvaxia) upon receipt of order, the FDA said. Let’s stop the hysteria and start with a basic fact: Dengvaxia works. That could be the cry at the moment. albopictus) mosquito. MANILA-- The controversial anti-dengue vaccine Dengvaxia is responsible for the deaths of a number of children, Public Attorney's Office (PAO) Chief Persida Acosta said Wednesday.. Acosta made the remarks in response to the claims of former President Benigno “Noynoy” Aquino III and former Health Secretary Janette Garin insisting that there has been no proof that the vaccine can cause deaths. Whereas Dengvaxia mainly triggers antibody production, the NIH vaccine stimulates a robust T cell response, which Halstead believes is the key to protection—and would avoid ADE. Today, Benigno Aquino III, the president at the time that the Philippines implemented a nationwide pediatric vaccination campaign with Dengvaxia in 2016, defended his decision to green-light the program, which has inoculated 830,000 children since April of last year, according to GMA News. So if you have had at least one episode of dengue (like me), you should absolutely not hesitate to get the vaccine. The first dengue vaccine, Dengvaxia® (CYD-TDV) developed by Sanofi Pasteur was licensed in December 2015 and has now been approved by regulatory authorities in ~20 countries. December 1, 2020. For the types 2 and 3, the vaccine is worse, sometimes only 30 percent. If vaccination helps more than hurts people, it should be done. Dengvaxia; Uses for Dengvaxia. “The dengue vaccine is very different from other vaccines,” he says. It is beneficial to far more than the very few it might hurt. Dengvaxia became commercially available in 2016, in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, … Dengvaxia is designed to protect against those severe infections by inoculating the patient with all four strains. Doctors must have proof of a prior dengue infection to ensure the vaccine is … Dengvaxia is approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas. Dengue is common in more than 100 countries around the world. In fact, 3.9 billion people live … Based on studies in the Philippines, 90% in those ages 12 and above in the Philippines have the dengue antibodies in their blood—that means that Dengvaxia would work for 90% of the population. What AstraZeneca? Here, Dean Blumberg, chief of pediatric infectious diseases at UC Davis Children’s Hospital, lays out the facts about some vaccine myths and explains the value and safety of the Pfizer and Moderna vaccines. Forty percent of the world’s population, about 3 billion people, live in areas with a risk of dengue. By Mauro Gia Samonte. Dengue virus is carried by the … A vaccination program had been run by the Philippine Department of Health who had administered Sanofi Pasteur's Dengvaxia to schoolchildren. The protection against re-infection by Dengvaxia is 60 percent. “ [With] most vaccines, you … The virus can last for up to 10 days. Indication: Indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. Herman Lumanog/Pacific Press/Sipa via AP. Dengvaxia (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue disease (dengue fever) caused by dengue virus serotypes 1, 2, 3, and 4. Dengvaxia ® (Dengue Tetravalent Vaccine, Live) is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4. The FDA has approved Dengvaxia, the first vaccine against dengue fever. FACTS. Dengvaxia is a weakened but live vaccine and works by triggering an immune response against four types of dengue virus. Florida What is Dengvaxia and what is it used for? Presidential spokesperson Harry Roque said … Dengvaxia Market Report Outlook 2021-2027 provides brief information related to specific growth opportunities including supply and demand scenario, pricing structure, profit margins. Dengvaxia reduces the chance of suffering a severe case of dengue by 93 percent. “Severe,” Bravo stressed, does not refer to the killer strain of dengue hemorrhagic fever. Dengue viruses are spread to people through the bite of an infected Aedes species ( Ae. The program was stopped when Sanofi … An estimated 500,000 people with severe dengue require hospitalization each year, and about 2.5% of those affected die from dengue 1. Remember Dengvaxia! Sign me up Offices District of Columbia 1100 Connecticut Ave. NW Suite 1300B Washington, DC 20036. Fact: The vaccines will not give you COVID-19. Back in the U.S., the FDA yesterday approved Dengvaxia for use here with one important restriction. The Philippines became the first country in Asia to approve the commercial sale of Dengvaxia, in December 2015. Dengue disease is a mosquito-borne tropical disease caused by the dengue virus leading to mild, flu- Each year, 390 million people are infected, of which 96 million people show clinical symptoms 1. The vaccine has 4 components, encoding for antigens of the four dengue virus strains. The vaccine, called Dengvaxia, is aimed at helping children in Puerto Rico and other U.S. territories where dengue is a problem. aegypti or Ae. Previous reports said 40,000 people from 15 countries participated in clinical tests, which revealed an 80% reduction in the risk of hospitalization after being administered the shot. The Dengvaxia controversy was a health scare in the Philippines caused when the dengue fever vaccine Dengvaxia was found to increase the risk of disease severity for some people who had received it. Common side effects of Dengvaxia include Dengvaxia is a vaccine used to help protect against dengue disease. Buddy Gomez -- Cyberbuddy. Dengvaxia (dengue tetravalent vaccine [live, attenuated]) An overview of Dengvaxia and why it is authorised in the EU . Licence clearance: Based on the database and the trial results in India, Sanofi is slated to apply for … Admittedly, AstraZeneca has never been tested yet on any people on earth. “FILIPINOS are no [guinea] pigs!”. Dengvaxia is the first dengue vaccine developed by Sanofi. Preventive medicine, especially for the underprivileged and the indigents, now encounters unwarranted scare. ";s:7:"keyword";s:21:"facts about dengvaxia";s:5:"links";s:787:"<a href="https://api.duassis.com/storage/q8q7nfc/harry-potter-fanfiction-harry-is-dying">Harry Potter Fanfiction Harry Is Dying</a>,
<a href="https://api.duassis.com/storage/q8q7nfc/steel-vengeance-inversions">Steel Vengeance Inversions</a>,
<a href="https://api.duassis.com/storage/q8q7nfc/robert-wolford-football">Robert Wolford Football</a>,
<a href="https://api.duassis.com/storage/q8q7nfc/sheffield-united-u23-vs-coventry-u23">Sheffield United U23 Vs Coventry U23</a>,
<a href="https://api.duassis.com/storage/q8q7nfc/safeway-canada-gift-baskets">Safeway Canada Gift Baskets</a>,
<a href="https://api.duassis.com/storage/q8q7nfc/ggpubr-boxplot-p-value">Ggpubr Boxplot P-value</a>,
<a href="https://api.duassis.com/storage/q8q7nfc/brooklyn-heights-ferry">Brooklyn Heights Ferry</a>,
";s:7:"expired";i:-1;}
Mini Shell